Driving growth & Getting ready for launch
Evotec SE, H1 2021 Interim Report, 11 August 2021
Cautionary statement regarding forward-looking statements
Information set forth in this presentation contains forward-looking statements, which involve a number of risks and
uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goal", "intend", "look forward to", "may", "plan", "potential", "predict", "project", "should", "will", "would" and similar expressions. The forward-looking statements
contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.
Note:
The operating business of Evotec GT commenced on 1 April 2020. In addition, the acquisition of the assets (mainly land and buildings) and the takeover of employees of the Biopark by Sanofi SAS in Toulouse became legally effective on 1 July 2020. The two entities were fully consolidated in the consolidated financial statements from the dates specified above.
PAGE 1
Welcome to H1 2021
The Management Team
Werner Lanthaler1) | Enno Spillner1) | Craig Johnstone | Cord Dohrmann | |||||||||||
CEO | CFO | COO | CSO | |||||||||||
PAGE 2 | 1) On the call for the H1 2021 interim report |
Agenda
Highlights
Financial performance H1 2021
"Building for growth"
Guidance 2021
PAGE 3
Strong overall performance and progress in all "lanes"
H1 2021 - Highlights & Lowlights
Highlights
- Business building accelerated, despite COVID-19
- Multiple new & extended integrated drug discovery and development alliances (EVOiR&D)
- J.POD® 1 US in Redmond opening August 18th;
construction of J.POD® 2 EU to start in Q4 2021 (EVOaccess) - Acquisition of Verona site completed - Now "Campus Levi-Montalcini"
- BMS Oncology protein degradation partnership - significant extension ahead of term
- New protein degradation collaboration in undisclosed therapeutic area also signed with BMS
- PRROTECT, an initiative for pandemic preparedness, launched
- Confidential submission of draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering of American Depositary Shares (after period-end)
- Positive Phase IIb results for Bayer's eliapixant in patients with refractory chronic cough (RCC) (after period-end) (EVOroyalty)
Lowlights
- Slight delays in milestones, but several important milestones imminent
PAGE 4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Evotec SE published this content on 12 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2021 15:41:02 UTC.